1. Varied functions of immune checkpoints during cancer metastasis

   • Ali Safarzadeh
   • Mohsen Alizadeh
   • Nicola Silvestris

   Review Open access 09 September 2020 Pages: 569 - 588

   

2. Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer

   • H. Adderley
   • F. H. Blackhall
   • C. R. Lindsay

   Review Open access 11 September 2020 Pages: 589 - 595

3. A systematic scoping review on natural killer cell function in colorectal cancer

   • Fiona S. W. Reid
   • Natasha Egoroff
   • Stephen R. Smith

   Review 11 September 2020 Pages: 597 - 606

   

4. Pembrolizumab and atezolizumab in triple-negative breast cancer

   • Dorota Kwapisz

   Review 05 October 2020 Pages: 607 - 617

5. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives

   • Jingjing Qu
   • Quanhui Mei
   • Jianying Zhou

   Review Open access 06 October 2020 Pages: 619 - 631

   

6. Anti-tumor and immune modulating activity of T cell induced tumor-targeting effectors (TITE)

   • Archana Thakur
   • Sri Vidya Kondadasula
   • Lawrence G. Lum

   Original Article 31 August 2020 Pages: 633 - 656

   

7. Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab

   • Toshiki Kijima
   • Hina Yamamoto
   • Yasuhisa Fujii

   Original Article 02 September 2020 Pages: 657 - 665

   

8. Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma

   • Huayu Yang
   • Lejia Sun
   • Yilei Mao

   Original Article 02 September 2020 Pages: 667 - 677

   

9. Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies

   • Alexandra Frelau
   • Xavier Palard-Novello
   • Antoine Girard

   Original Article 03 September 2020 Pages: 679 - 687

   

10. Monophosphoryl lipid A-induced activation of plasmacytoid dendritic cells enhances the anti-cancer effects of anti-PD-L1 antibodies

    • Wei Zhang
    • Seong-Min Lim
    • Jun-O Jin

    Original Article 09 September 2020 Pages: 689 - 700

    

11. Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study

    • Qinchuan Wang
    • Yuanqing Ye
    • Xifeng Wu

    Original Article Open access 09 September 2020 Pages: 701 - 712

    

12. Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase

    • Qi Xiong
    • Ziwei Huang
    • Yi Hu

    Original Article 10 September 2020 Pages: 713 - 720

    

13. Next-generation humanized patient-derived xenograft mouse model for pre-clinical antibody studies in neuroblastoma

    • Rosa Nguyen
    • Anand G. Patel
    • Michael A. Dyer

    Original Article 11 September 2020 Pages: 721 - 732

    

14. Reviving up dendritic cells can run cancer immune wheel in non-small cell lung cancer: a prospective two-arm study

    • Asmaa M. Zahran
    • Helal F. Hetta
    • Amal Rayan

    Original Article 12 September 2020 Pages: 733 - 742

    

15. A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC)

    • J. Chandra
    • W. P. Woo
    • Sandro V. Porceddu

    Original Article 12 September 2020 Pages: 743 - 753

    

16. Flow cytometric analysis of circulating endothelial cells and endothelial progenitor cells in pediatric solid tumors: prognostic impact on treatment response and survival

    • Heba Abdel Razik Sayed
    • Helal F. Hetta
    • Asmaa M. Zahran

    Original Article 18 September 2020 Pages: 755 - 761

    

17. Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors

    • Kyriakos P. Papadopoulos
    • Nehal Lakhani
    • Judy S. Wang

    Original Article Open access 28 September 2020 Pages: 763 - 772

    

18. Systematic analysis of immune-related genes based on a combination of multiple databases to build a diagnostic and a prognostic risk model for hepatocellular carcinoma

    • Di-guang Wen
    • Xiao-ping Zhao
    • Zuo-jin Liu

    Original Article 28 September 2020 Pages: 773 - 786

    

19. Anti-leukemia effect associated with down-regulated CD47 and up-regulated calreticulin by stimulated macrophages in co-culture

    • Eman M. Hassan
    • Gilbert C. Walker
    • Shan Zou

    Original Article 29 September 2020 Pages: 787 - 801

    

20. Differential gene expression of tumor-infiltrating CD33⁺ myeloid cells in advanced- versus early-stage colorectal cancer

    • Salman M. Toor
    • Rowaida Z. Taha
    • Eyad Elkord

    Original Article Open access 30 September 2020 Pages: 803 - 815

    

21. Downregulated ATP6V1B1 expression acidifies the intracellular environment of cancer cells leading to resistance to antibody-dependent cellular cytotoxicity

    • Mariko Nishie
    • Eiji Suzuki
    • Masakazu Toi

    Original Article 30 September 2020 Pages: 817 - 830

    

22. High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient

    • Elena Anghileri
    • Natalia Di Ianni
    • Serena Pellegatta

    Original Article 03 November 2020 Pages: 831 - 842

    

23. PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures

    • Kathryn M. Appleton
    • Ashley K. Elrod
    • Teresa M. DesRochers

    Original Article 25 January 2021 Pages: 843 - 856

    

24. Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study

    • Haiping Jiang
    • Yulong Zheng
    • Nong Xu

    Clinical Trial Report Open access 17 October 2020 Pages: 857 - 868

    

25. Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas

    • Daniel J. Landsburg
    • Alexa Koike
    • Gabriel C. Caponetti

    Research Report 28 August 2020 Pages: 869 - 874